Advertisement
Journal Home
Search for

Volume 193, Issue 6, Pages 2010-2016 (December 2005)


View previous. 23 of 69 View next.

Activity of hepatic enzymes from week sixteen of pregnancy

Angeles Ruiz-Extremera, MDaCorresponding Author Informationemail address, María A. López-Garrido, MDb, Enriqueta Barranco, MDc, María D. Quintero, MDb, Esther Ocete-Hita, MDa, Paloma Muñoz de Rueda, PhDb, Ana Gila, MDb, Javier Salmerón, MDb

Received 17 December 2004; accepted 19 April 2005.

Objective

This study was undertaken to determine the prevalence, epidemiology, and mother-child repercussions of increased alanine-aminotransferase levels from week 16 of pregnancy.

Study design

A longitudinal observational study of 381 pregnant women. The cause of increased alanine-aminotransferase levels during pregnancy and repercussions on the neonate were studied in 283 cases. Statistical analysis was performed with Mann-Whitney test, χ2 test, or the Fisher exact test.

Results

The mean age of the mothers was 29.9 ± 4.8 years. Twenty-five percent presented increased gamma-glutamyl-transpeptidase, alkaline phophatase, and dehydrogenase lactate from week 32. Increased alanine-aminotransferase was observed in 7.4% (95% CI, 5.00%-10.57%) of cases. Clinical disorders were light, transitory, and with no apparent cause, except for 1 hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome, 3 preeclampsias, and 1 gravidic cholestasis. No statistically significant differences were observed in the group of mother-child with alanine-aminotransferase normal or increased.

Conclusion

Most increases in alanine-aminotransferase from week 16 of pregnancy are transitory, non-specific, and have no repercussions on mother or child.

a Pediatrics Service

b Gastroenterology Unit

c Department of Obstetrics and Gynecology, H. Universitario San Cecilio, Granada, Spain

Corresponding Author InformationReprint requests: Angeles Ruiz-Extremera, MD, Department of Pediatrics, “San Cecilio” University Hospital, Avda Dr Oloriz no 16, 18012- Granada, Spain.

 Support provided by the Government of Spain FIS 97/0378 and Instituto de Salud “Carlos III” RNIHG C03/02.

PII: S0002-9378(05)00604-6

doi:10.1016/j.ajog.2005.04.045


View previous. 23 of 69 View next.

Advertisement